For: | Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i44/9674.htm |
Number | Citing Articles |
1 |
Masahiro Ohira, Shou Tanaka, Yasuhiro Watanabe, Shoko Nakamura, Rena Oka, Takashi Yamaguchi, Noriko Ban, Atsuhito Saiki, Noriko Ishihara, Takeyoshi Murano, Takayo Murase, Takashi Nakamura, Ichiro Tatsuno. Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction. The American Journal of the Medical Sciences 2022; 363(3): 242 doi: 10.1016/j.amjms.2021.09.011
|
2 |
Adrian Curran, Anna Rull, Jordi Navarro, Judit Vidal-González, Mario Martin-Castillo, Joaquin Burgos, Vicenç Falcó, Esteban Ribera, Ariadna Torrella, Bibiana Planas, Joaquim Peraire, Manuel Crespo. Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. Journal of Clinical Medicine 2020; 9(5): 1246 doi: 10.3390/jcm9051246
|
3 |
Yi-Hao Yen, Fang-Ying Kuo, Kwong-Ming Kee, Kuo-Chin Chang, Ming-Chao Tsai, Tsung-Hui Hu, Sheng-Nan Lu, Jing-Houng Wang, Chao-Hung Hung, Chien-Hung Chen. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. Digestive and Liver Disease 2019; 51(1): 142 doi: 10.1016/j.dld.2018.07.003
|
4 |
Amedeo Lonardo, Stefano Ballestri, Giovanni Targher. “ Not all forms of NAFLD were created equal ”. Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?. Atherosclerosis 2017; 257: 253 doi: 10.1016/j.atherosclerosis.2017.01.008
|
5 |
Hyun-Woo Joo, Yi-Sun Song, In-Hwa Park, Guang-Yin Shen, Jin-Hee Seong, Na-Kyoung Shin, A-Hyeon Lee, Hyuck Kim, Kyung-Soo Kim. Granulocyte Colony Stimulating Factor Ameliorates Hepatic Steatosis Associated with Improvement of Autophagy in Diabetic Rats. Canadian Journal of Gastroenterology and Hepatology 2020; 2020: 1 doi: 10.1155/2020/2156829
|
6 |
Zahid Hussain, Muhammad Aslam Rind, Maria Nazir, Muhammad Saleem. Assessment of Risk Factors for Non-Alcoholic Fatty Liver Disease (NAFLD). Pakistan Journal of Health Sciences 2023; : 187 doi: 10.54393/pjhs.v4i05.773
|
7 |
Vinay Narladkar, Aman Agrawal, Sanket S Bakshi, Swarupa Chakole, Aniket G Pathade, Seema Yelne. Unravelling the Interplay: Exploring the Influence of Previous Hepatitis B Virus, Hepatitis A Virus, and Hepatitis E Virus Infections on Non-alcoholic Fatty Liver Disease. Cureus 2023; doi: 10.7759/cureus.44969
|
8 |
Farouk K. El-Baz, Dalia O. Saleh, Gehad A. Abdel Jaleel, Rehab A. Hussein. Attenuation of Age-Related Hepatic Steatosis by Dunaliella salina Microalgae in Senescence Rats through the Regulation of Redox Status, Inflammatory Indices, and Apoptotic Biomarkers. Advances in Pharmacological and Pharmaceutical Sciences 2020; 2020: 1 doi: 10.1155/2020/3797218
|
9 |
Marian-Sorin Popescu, Andrei Ioan Drocas, Andrei Osman, Dan-Mihai Firu, Vlad Pădureanu, Cristina Maria Mărginean, Daniel-Cristian Pîrvu, Radu Mitruț, Dragoș Nicolae Mărgăritescu, Antonia Radu, Daniela Calina, Anca Oana Docea, Paul Mitruț. The Extent of Insulin Resistance in Patients That Cleared Viral Hepatitis C Infection and the Role of Pre-Existent Type 2 Diabetes Mellitus: A Meta-Analysis. Reports 2022; 5(4): 42 doi: 10.3390/reports5040042
|
10 |
A A Svistunov, M A Osadchuk, N V Kireeva, M M Osadchuk. Optimizing therapy of liver diseases not associated with viral infection. Terapevticheskii arkhiv 2018; 90(2): 94 doi: 10.26442/terarkh2018902105-111
|
11 |
Duanghathai Pasanta, Montree Tungjai, Sirirat Chancharunee, Warayuth Sajomsang, Suchart Kothan. Body mass index and its effects on liver fat content in overweight and obese young adults by proton magnetic resonance spectroscopy technique. World Journal of Hepatology 2018; 10(12): 924-933 doi: 10.4254/wjh.v10.i12.924
|
12 |
Gabriella Bueno Marinho, Jefferson Rocha Tenório, Luciana Munhoz, Natália Silva Andrade, Emiko Saito Arita, Karem L. Ortega. Detection of calcified atheromas on panoramic radiographs of cirrhotic patients. Special Care in Dentistry 2021; 41(2): 164 doi: 10.1111/scd.12551
|
13 |
Soon Sun Kim, Hyo Jung Cho, Hyun Ji Kim, Dae Ryong Kang, Jacob R. Berry, Jin Hong Kim, Min Jae Yang, Sun Gyo Lim, SooJin Kim, Jae Youn Cheong, Sung Won Cho. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Digestive and Liver Disease 2018; 50(4): 370 doi: 10.1016/j.dld.2017.12.018
|
14 |
Laury Sellem, Kim G. Jackson, Laura Paper, Ian D. Givens, Julie A. Lovegrove. Can individual fatty acids be used as functional biomarkers of dairy fat consumption in relation to cardiometabolic health? A narrative review. British Journal of Nutrition 2022; 128(12): 2373 doi: 10.1017/S0007114522000289
|
15 |
Makan Cheraghpour, Hossein Imani, Shahrzad Ommi, Seyed Moayed Alavian, Elahe Karimi‐Shahrbabak, Mehdi Hedayati, Zahra Yari, Azita Hekmatdoost. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial. Phytotherapy Research 2019; 33(8): 2118 doi: 10.1002/ptr.6406
|
16 |
Yebei Liang, Mao Ye, Xuhong Hou, Peizhu Chen, Li Wei, Fusong Jiang, Liang Feng, Lichang Zhong, Huaiyu Liu, Yuqian Bao, Weiping Jia. Development and validation of screening scores of non-alcoholic fatty liver disease in middle-aged and elderly Chinese. Diabetes Research and Clinical Practice 2020; 169: 108385 doi: 10.1016/j.diabres.2020.108385
|
17 |
Ravirajsinh N. Jadeja, Malita A. Jones, Ollya Fromal, Folami L. Powell, Sandeep Khurana, Nagendra Singh, Pamela M. Martin. Loss of GPR109A/HCAR2 induces aging-associated hepatic steatosis. Aging 2019; 11(2): 386 doi: 10.18632/aging.101743
|
18 |
Katti R. Crakes, Clarissa Santos Rocha, Irina Grishina, Lauren A. Hirao, Eleonora Napoli, Christopher A. Gaulke, Anne Fenton, Sandipan Datta, Juan Arredondo, Maria L. Marco, Sumathi Sankaran-Walters, Gino Cortopassi, Cecilia Giulivi, Satya Dandekar. PPARα-targeted mitochondrial bioenergetics mediate repair of intestinal barriers at the host–microbe intersection during SIV infection. Proceedings of the National Academy of Sciences 2019; 116(49): 24819 doi: 10.1073/pnas.1908977116
|
19 |
So Hee Park, Jiyun Park, So Yoon Kwon, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Janghyun Koh, Jae Hwan Jee, Jae Hyeon Kim, Mira Kang, Sang-Man Jin. Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-37858-8
|
20 |
Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Naga P. Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary D. Goodman, Keith Lindor. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018; 68(1): 361 doi: 10.1002/hep.29724
|
21 |
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel, J.A. Velarde-Ruiz Velasco. The Mexican consensus on nonalcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2019; 84(1): 69 doi: 10.1016/j.rgmxen.2019.02.003
|
22 |
Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen. Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes. Fibrosis 2024; 2(1): 10006 doi: 10.70322/fibrosis.2024.10006
|
23 |
Juergen Eckel. The Cellular Secretome and Organ Crosstalk. 2018; : 117 doi: 10.1016/B978-0-12-809518-8.00005-2
|
24 |
Ivan Linares, Matyas Hamar, Nazia Selzner, Markus Selzner. Steatosis in Liver Transplantation: Current Limitations and Future Strategies. Transplantation 2019; 103(1): 78 doi: 10.1097/TP.0000000000002466
|
25 |
Alaa Badawi, Giancarlo Di Giuseppe, Alind Gupta, Abbey Poirier, Paul Arora. Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection. BMJ Open 2020; 10(5): e035867 doi: 10.1136/bmjopen-2019-035867
|
26 |
Netanya S Utay, Douglas W Kitch, Eunice Yeh, Carl J Fichtenbaum, Michael M Lederman, Jacob D Estes, Claire Deleage, Clara Magyar, Scott D Nelson, Karen L Klingman, Barbara Bastow, Amneris E Luque, Grace A McComsey, Daniel C Douek, Judith S Currier, Jordan E Lake, Francesca Aweeka, Jenifer Baer, Alex Benns, Joan Dragavon, Christopher Hensel, Priscilla Hsue, Andy Kaytes, Heather Ribaudo, David Rusin, Katherine Shin, Antoine Simmons, Xinyan Zhan. Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. The Journal of Infectious Diseases 2018; 217(11): 1770 doi: 10.1093/infdis/jiy064
|
27 |
Zobair M. Younossi, Rohit Loomba, Quentin M. Anstee, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Zachary D. Goodman, Naga P. Chalasani, Kris V. Kowdley, Jacob George, Keith Lindor. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018; 68(1): 349 doi: 10.1002/hep.29721
|
28 |
Zobair M. Younossi, Pegah Golabi, Leyla de Avila, James Minhui Paik, Manirath Srishord, Natsu Fukui, Ying Qiu, Leah Burns, Arian Afendy, Fatema Nader. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology 2019; 71(4): 793 doi: 10.1016/j.jhep.2019.06.021
|
29 |
Evangelista Sagnelli, Caterina Sagnelli, Antonio Russo, Mariantonietta Pisaturo, Clarissa Camaioni, Roberta Astorri, Nicola Coppola. Advances in Microbiology, Infectious Diseases and Public Health. Advances in Experimental Medicine and Biology 2020; 1323: 115 doi: 10.1007/5584_2020_604
|
30 |
Phumelele Yvonne Siphepho, Yi-Ting Liu, Ciniso Sylvester Shabangu, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Ming-Lung Yu, Shu-Chi Wang. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines 2021; 9(10): 1491 doi: 10.3390/biomedicines9101491
|
31 |
Yoosun Cho, Yoosoo Chang, Seungho Ryu, Sarah H. Wild, Christopher D. Byrne. Nonalcoholic fatty liver disease without overlapping metabolic‐associated fatty liver disease and the risk of incident type 2 diabetes. Liver International 2023; 43(11): 2445 doi: 10.1111/liv.15661
|
32 |
Narjeet S. Khurmi, Yu‐Hui Chang, D. Eric Steidley, Andrew L. Singer, Winston R. Hewitt, Kunam S. Reddy, Adyr A. Moss, Amit K. Mathur. Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States†. Liver Transplantation 2018; 24(10): 1398 doi: 10.1002/lt.25055
|
33 |
Zheng Li, Zongtao Zhou, Lijun Hu, Liming Deng, Qiang Ren, Luyong Zhang. ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis. Pharmacological Research 2020; 159: 105035 doi: 10.1016/j.phrs.2020.105035
|
34 |
Cassidy Williams, Festus Kamau, Frans Everson, Boipelo Kgokane, Patrick De Boever, Nandu Goswami, Ingrid Webster, Hans Strijdom. HIV and Antiretroviral Therapy Are Independently Associated with Cardiometabolic Variables and Cardiac Electrical Activity in Adults from the Western Cape Region of South Africa. Journal of Clinical Medicine 2021; 10(18): 4112 doi: 10.3390/jcm10184112
|
35 |
Lan Bai, Hongliang Li. Innate immune regulatory networks in hepatic lipid metabolism. Journal of Molecular Medicine 2019; 97(5): 593 doi: 10.1007/s00109-019-01765-1
|
36 |
Geru Tao, Guangjie Zhang, Wei Chen, Chao Yang, Yazhuo Xue, Guohua Song, Shucun Qin. A randomized, placebo‐controlled clinical trial of hydrogen/oxygen inhalation for non‐alcoholic fatty liver disease. Journal of Cellular and Molecular Medicine 2022; 26(14): 4113 doi: 10.1111/jcmm.17456
|
37 |
Vincenza Di Stasi, Elisa Maseroli, Giulia Rastrelli, Irene Scavello, Sarah Cipriani, Tommaso Todisco, Sara Marchiani, Flavia Sorbi, Massimiliano Fambrini, Felice Petraglia, Mario Maggi, Linda Vignozzi. SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.641446
|
38 |
Fariba Ahmadizar, Zobair M. Younossi. Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals With Type 2 Diabetes Mellitus. Journal of Clinical Gastroenterology 2024; doi: 10.1097/MCG.0000000000002079
|
39 |
Sui-Weng Wong, Wah-Kheong Chan. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian Journal of Gastroenterology 2020; 39(1): 1 doi: 10.1007/s12664-020-01018-x
|
40 |
Fatemeh Kazeminasab, Sayed Mohammad Marandi, Maryam Baharlooie, Mohammad Hossein Nasr-Esfahani, Kamran Ghaedi. Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice. Nutrition & Metabolism 2021; 18(1) doi: 10.1186/s12986-021-00600-0
|
41 |
S Singh, KK Kharbanda. Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review. Archives of Hepatitis Research 2017; 3(1): 029 doi: 10.17352/ahr.000014
|
42 |
Jordan E. Lake. The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection. Current HIV/AIDS Reports 2017; 14(6): 211 doi: 10.1007/s11904-017-0368-6
|
43 |
Yujin Ding, Guangdi Li, Zhiguang Zhou, Tuo Deng. Molecular mechanisms underlying hepatitis C virus infection-related diabetes. Metabolism 2021; 121: 154802 doi: 10.1016/j.metabol.2021.154802
|
44 |
Yutaka Takahashi. The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. International Journal of Molecular Sciences 2017; 18(7): 1447 doi: 10.3390/ijms18071447
|
45 |
Stanislav Kotlyarov. Immune and metabolic cross-links in the pathogenesis of comorbid non-alcoholic fatty liver disease. World Journal of Gastroenterology 2023; 29(4): 597-615 doi: 10.3748/wjg.v29.i4.597
|
46 |
Thomas Marjot, Ahmad Moolla, Jeremy F Cobbold, Leanne Hodson, Jeremy W Tomlinson. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews 2020; 41(1): 66 doi: 10.1210/endrev/bnz009
|
47 |
Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Takashi Miki, Hironobu Toda, Kentaro Ejiri, Masatoki Yoshida, Yusuke Nanba, Masashi Yoshida, Kazufumi Nakamura, Hiroshi Morita, Hiroshi Ito. Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study. Cardiovascular Diabetology 2021; 20(1) doi: 10.1186/s12933-020-01192-4
|
48 |
Veera Houttu, Susanne Csader, Max Nieuwdorp, Adriaan G. Holleboom, Ursula Schwab. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Frontiers in Nutrition 2021; 8 doi: 10.3389/fnut.2021.716783
|
49 |
Takumi Kawaguchi, Hironori Koga, Takuji Torimura. Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. Current Hepatology Reports 2017; 16(4): 317 doi: 10.1007/s11901-017-0370-x
|
50 |
Yi-Jing Sheen, Chih-Cheng Hsu, Pei-Tseng Kung, Li-Ting Chiu, Wen-Chen Tsai. Impact of chronic hepatitis on cardiovascular events among type 2 diabetes patients in Taiwan pay-for-performance program. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-15827-x
|
51 |
Yoshitaka Hashimoto, Masahide Hamaguchi, Muhei Tanaka, Akihiro Obora, Takao Kojima, Michiaki Fukui. Metabolically healthy obesity without fatty liver and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. Obesity Research & Clinical Practice 2018; 12(1): 4 doi: 10.1016/j.orcp.2017.12.003
|
52 |
Giovanni Guaraldi, Amedeo Lonardo, Liliana Maia, Frank J. Palella. Metabolic concerns in aging HIV-infected persons. AIDS 2017; 31(Supplement 2): S147 doi: 10.1097/QAD.0000000000001483
|
53 |
Sukhpreet Singh, Natalia A Osna, Kusum K Kharbanda. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World Journal of Gastroenterology 2017; 23(36): 6549-6570 doi: 10.3748/wjg.v23.i36.6549
|
54 |
Guglielmo M Trovato. Non-alcoholic fatty liver disease and Atherosclerosis at a crossroad: The overlap of a theory of change and bioinformatics. World Journal of Gastrointestinal Pathophysiology 2020; 11(3): 57-63 doi: 10.4291/wjgp.v11.i3.57
|
55 |
T. A. Shekhovtsova, D. V. Duplyakov. HIV infection and cardiovascular pathology. Cardiovascular Therapy and Prevention 2023; 22(3): 3370 doi: 10.15829/1728-8800-2023-3370
|
56 |
Oren Tirosh, Anna M. Giudetti. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression. Oxidative Medicine and Cellular Longevity 2018; 2018(1) doi: 10.1155/2018/2548154
|
57 |
Gabriel Tayguara Silveira Guerreiro, Larisse Longo, Mariana Alves Fonseca, Valessa Emanoele Gabriel de Souza, Mário Reis Álvares-da-Silva. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?. Hepatology International 2021; 15(2): 380 doi: 10.1007/s12072-021-10157-y
|
58 |
Adriana Cervo, Giada Sebastiani, Jovana Milic, Thomas Krahn, Sergio Mazzola, Salvatore Petta, Antonio Cascio, Giovanni Guaraldi, Giovanni Mazzola. “Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”. HIV Medicine 2022; 23(8): 911 doi: 10.1111/hiv.13274
|
59 |
Ludovico Abenavoli, Marta Greco, Natasa Milic, Francesca Accattato, Daniela Foti, Elio Gulletta, Francesco Luzza. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients 2017; 9(8): 870 doi: 10.3390/nu9080870
|
60 |
Arunkumar Krishnan, Omar T. Sims, Phani Keerthi Surapaneni, Tinsay A. Woreta, Saleh A. Alqahtani. Risk of adverse cardiovascular outcomes among people with HIV and nonalcoholic fatty liver disease. AIDS 2023; 37(8): 1209 doi: 10.1097/QAD.0000000000003537
|
61 |
Bing bing Chen, Ying Han, Xinting Pan, Jianhui Yan, Wenjuan Liu, Yangfan Li, Xu Lin, Shanghua Xu, Xian-E Peng. Association between nut intake and non-alcoholic fatty liver disease risk: a retrospective case-control study in a sample of Chinese Han adults. BMJ Open 2019; 9(9): e028961 doi: 10.1136/bmjopen-2019-028961
|
62 |
P. Vineeth Daniel, Surbhi Dogra, Priya Rawat, Abhinav Choubey, Aiysha Siddiq Khan, Sangam Rajak, Mohan Kamthan, Prosenjit Mondal. NF-κB p65 regulates hepatic lipogenesis by promoting nuclear entry of ChREBP in response to a high carbohydrate diet. Journal of Biological Chemistry 2021; 296: 100714 doi: 10.1016/j.jbc.2021.100714
|
63 |
Pratima Dibba, Rosann Cholankeril, Andrew A. Li, Meera Patel, Mariam Fayek, Christy Dibble, Nnenna Okpara, Autumn Hines, Aijaz Ahmed. Hepatitis C in Pregnancy. Diseases 2018; 6(2): 31 doi: 10.3390/diseases6020031
|
64 |
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel, J.A. Velarde-Ruiz Velasco. Consenso mexicano de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 2019; 84(1): 69 doi: 10.1016/j.rgmx.2018.11.007
|
65 |
Violeta Raverdy, Estelle Chatelain, Guillaume Lasailly, Robert Caiazzo, Jimmy Vandel, Helene Verkindt, Camille Marciniak, Benjamin Legendre, Pierre Bauvin, Naima Oukhouya‐Daoud, Gregory Baud, Mikael Chetboun, Marie‐Christine Vantyghem, Viviane Gnemmi, Emmanuelle Leteurtre, Bart Staels, Philippe Lefebvre, Philippe Mathurin, Guillemette Marot, Francois Pattou. Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study. Obesity 2023; 31(12): 3066 doi: 10.1002/oby.23904
|
66 |
Maria J. Peláez-Jaramillo, Allison A. Cárdenas-Mojica, Paula V. Gaete, Carlos O. Mendivil. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. Diabetes Therapy 2018; 9(2): 521 doi: 10.1007/s13300-018-0374-8
|
67 |
Maja Ružić, Rinaldo Pellicano, Milotka Fabri, Francesco Luzza, Luigi Boccuto, Snežana Brkić, Ludovico Abenavoli. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Medica 2018; 60(4) doi: 10.23736/S0031-0808.18.03472-9
|
68 |
Amedeo Lonardo, Ayako Suzuki. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. Journal of Clinical Medicine 2020; 9(5): 1278 doi: 10.3390/jcm9051278
|
69 |
Rohit Loomba, Robert Wong, Jeremy Fraysse, Sanatan Shreay, Suying Li, Stephen Harrison, Stuart C. Gordon. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Alimentary Pharmacology & Therapeutics 2020; 51(11): 1149 doi: 10.1111/apt.15679
|
70 |
Qiang Zhang, Qiongyun Chen, Changsheng Yan, Chunyan Niu, Jingping Zhou, Jingjing Liu, Yang Song, Fei Zhou, Yanyun Fan, Jianlin Ren, Hongzhi Xu, Bangzhou Zhang. The Absence of STING Ameliorates Non-Alcoholic Fatty Liver Disease and Reforms Gut Bacterial Community. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.931176
|
71 |
Dong-Woo Lim, Hyuck Kim, Seung-Jun Lee, Ga-Ram Yu, Jai-Eun Kim, Won-Hwan Park. Jwa Kum Whan Attenuates Nonalcoholic Fatty Liver Disease by Modulating Glucose Metabolism and the Insulin Signaling Pathway. Evidence-Based Complementary and Alternative Medicine 2019; 2019: 1 doi: 10.1155/2019/4589810
|
72 |
Filippo Valbusa, Stefano Bonapace, Davide Agnoletti, Luca Scala, Cristina Grillo, Pietro Arduini, Emanuela Turcato, Alessandro Mantovani, Giacomo Zoppini, Guido Arcaro, Christopher Byrne, Giovanni Targher, Anna Alisi. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLOS ONE 2017; 12(3): e0173398 doi: 10.1371/journal.pone.0173398
|
73 |
Catalina Mihai, Bogdan Mihai, Anca Trifan, Carol Stanciu, Liana Gheorghe, Mircea Diculescu, Manuela Curescu, Ciprian Brisc, Adrian Goldis, Simona Bataga, Larisa Sandulescu, Ion Rogoveanu, Andrada Seicean, Cristina Cijevschi Prelipcean. Metabolic Syndrome and Genotype 1 Virus C Compensated Liver Cirrhosis in the Era of Directly Acting Antiviral Therapy. Hepatitis Monthly 2017; 17(7) doi: 10.5812/hepatmon.58022
|
74 |
Fatemeh Farshadpour, Reza Taherkhani, Mohammad Reza Ravanbod, Seyed Sajjad Eghbali. Prevalence and Genotype Distribution of Hepatitis C Virus Infection among Patients with Type 2 Diabetes Mellitus. Medical Principles and Practice 2018; 27(4): 308 doi: 10.1159/000488985
|
75 |
Chen‐hao Zhang, Yifei Cheng, Shu Zhang, Jia Fan, Qiang Gao. Changing epidemiology of hepatocellular carcinoma in Asia. Liver International 2022; 42(9): 2029 doi: 10.1111/liv.15251
|
76 |
Azin Vakilpour, Ehsan Amini-Salehi, Arman Soltani Moghadam, Mohammad-Hossein Keivanlou, Negin Letafatkar, Arman Habibi, Mohammad Hashemi, Negar Eslami, Reza Zare, Naeim Norouzi, Hamed Delam, Farahnaz Joukar, Fariborz Mansour-Ghanaei, Soheil Hassanipour, Sandeep Samethadka Nayak. The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review. Nutrition & Diabetes 2024; 14(1) doi: 10.1038/s41387-024-00281-7
|
77 |
Hua Liu, Yang-Min Hao, Sheng Jiang, Maiheliya Baihetiyaer, Cheng Li, Guo-Yao Sang, Zhiming Li, Guo-Li Du. Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment. International Journal of General Medicine 2024; : 2613 doi: 10.2147/IJGM.S460200
|
78 |
Amedeo Lonardo, Stefano Ballestri. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020; 1(3): 85 doi: 10.37349/emed.2020.00007
|
79 |
Bahare Fazeli, Daniela Ligi, Shayan Keramat, Rosanna Maniscalco, Hiva Sharebiani, Ferdinando Mannello. Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences. Diagnostics 2021; 11(10): 1736 doi: 10.3390/diagnostics11101736
|
80 |
Chao Chen, Kunhuan Yang, Yuhan Zhang, Meiqi Lu, Xiaoyan Zhao, Zheng Wan. Pathogenic gene connections in type 2 diabetes and non-alcoholic fatty liver disease: a bioinformatics analysis and mouse model investigations experiments. Nutrition & Diabetes 2024; 14(1) doi: 10.1038/s41387-024-00323-0
|
81 |
Fabio Nascimbeni, Stefano Ballestri, Mariana Verdelho Machado, Alessandro Mantovani, Helena Cortez-Pinto, Giovanni Targher, Amedeo Lonardo. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018; 12(4): 351 doi: 10.1080/17474124.2018.1415756
|
82 |
Trevor J. Orchard, Bertrand Cariou, Margery A. Connelly, James D. Otvos, Shuyu Zhang, Caryl J. Antalis, Tibor Ivanyi, Byron J. Hoogwerf. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes. Cardiovascular Diabetology 2017; 16(1) doi: 10.1186/s12933-017-0555-1
|
83 |
Nilesh Toke, Ajit Rathod, Pooja Phalak, Vikas Patel. Endothelial dysfunction and cardiovascular risk in non-alcoholic fatty liver disease – a systematic review and meta-analysis. Egyptian Liver Journal 2024; 14(1) doi: 10.1186/s43066-024-00348-1
|
84 |
M. A. Arzhakova, T. A. Shekhovtsova, D. V. Duplyakov. Coronary Heart Disease in HIV-Infected Patients. Rational Pharmacotherapy in Cardiology 2020; 15(6): 900 doi: 10.20996/1819-6446-2019-15-6-900-905
|
85 |
Shao Mei Sun, Yan Yan Wang, Qing Zhang, Li Liu, Ge Meng, Zhan Xin Yao, Hong Mei Wu, Yang Xia, Xue Bao, Ye Qing Gu, Hong Lei Wang, Hong Bin Shi, Hai Yan Xu, Xing Wang, Ming Zhou, Huan Li Jiao, Qi Yu Jia, Bang Mao Wang, Kai Jun Niu. Serum levels of immunoglobulins in an adult population and their relationship with nonalcoholic fatty liver disease. Journal of Digestive Diseases 2018; 19(8): 498 doi: 10.1111/1751-2980.12646
|
86 |
Francesco Bifari, Roberto Manfrini, Michele Dei Cas, Cesare Berra, Matteo Siano, Massimo Zuin, Rita Paroni, Franco Folli. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacological Research 2018; 137: 219 doi: 10.1016/j.phrs.2018.09.025
|
87 |
Amedeo Lonardo, Simonetta Lugari, Stefano Ballestri, Fabio Nascimbeni, Enrica Baldelli, Mauro Maurantonio. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?. Acta Diabetologica 2019; 56(4): 385 doi: 10.1007/s00592-018-1266-0
|
88 |
Lesley Hoyles, José-Manuel Fernández-Real, Massimo Federici, Matteo Serino, James Abbott, Julie Charpentier, Christophe Heymes, Jèssica Latorre Luque, Elodie Anthony, Richard H. Barton, Julien Chilloux, Antonis Myridakis, Laura Martinez-Gili, José Maria Moreno-Navarrete, Fadila Benhamed, Vincent Azalbert, Vincent Blasco-Baque, Josep Puig, Gemma Xifra, Wifredo Ricart, Christopher Tomlinson, Mark Woodbridge, Marina Cardellini, Francesca Davato, Iris Cardolini, Ottavia Porzio, Paolo Gentileschi, Frédéric Lopez, Fabienne Foufelle, Sarah A. Butcher, Elaine Holmes, Jeremy K. Nicholson, Catherine Postic, Rémy Burcelin, Marc-Emmanuel Dumas. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nature Medicine 2018; 24(7): 1070 doi: 10.1038/s41591-018-0061-3
|
89 |
Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng. High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare. BMC Public Health 2024; 24(1) doi: 10.1186/s12889-024-17851-0
|
90 |
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. Journal of Diabetes and its Complications 2017; 31(3): 521 doi: 10.1016/j.jdiacomp.2016.12.006
|
91 |
Kaveh Naseri, Saeede Saadati, Zahra Yari, Behzad Askari, Davood Mafi, Pooria Hoseinian, Omid Asbaghi, Azita Hekmatdoost, Barbora de Courten. Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2022; 14(15): 3224 doi: 10.3390/nu14153224
|
92 |
Vita Dikariyanto, Leanne Smith, Lucy Francis, May Robertson, Eslem Kusaslan, Molly O’Callaghan-Latham, Camille Palanche, Maria D’Annibale, Dimitra Christodoulou, Nicolas Basty, Brandon Whitcher, Haris Shuaib, Geoffrey Charles-Edwards, Philip J Chowienczyk, Peter R Ellis, Sarah EE Berry, Wendy L Hall. Snacking on whole almonds for 6 weeks improves endothelial function and lowers LDL cholesterol but does not affect liver fat and other cardiometabolic risk factors in healthy adults: the ATTIS study, a randomized controlled trial. The American Journal of Clinical Nutrition 2020; 111(6): 1178 doi: 10.1093/ajcn/nqaa100
|
93 |
Amedeo Lonardo, Alessandro Mantovani. Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. Nutrition, Metabolism and Cardiovascular Diseases 2021; 31(8): 2354 doi: 10.1016/j.numecd.2021.05.019
|